- PFMD is an independent collaborative initiative working to make patient engagement happen throughout the lifecycle of drug development.
- Servier is committed, as part of its “Patient-In” policy, to working with and for patients to provide innovative therapeutic solutions that best meets their needs.
- Partnership gives Servier the opportunity to help shape the future of patient engagement and access to tools and methodologies designed to catalyze systematic patient engagement.
Paris, October 25, 2018 – Servier, an independent international pharmaceutical company governed by a foundation, has joined the Patient-Focused Medicines Development (PFMD) partnership coalition. The aim of this collaboration is to strengthen the involvement of patients, who are increasingly co-actors in their health, in the Group’s innovation strategy.
PFMD is an independent collaboration of healthcare stakeholders partnering to operationalize patient engagement throughout the lifecycle of drug development. By developing new tools, methodologies and guidelines, it is helping organizations to embed patient engagement throughout the drug development lifecycle. It offers training and knowledge exchange opportunities, as well as access to the Patient Engagement Management Suite (PEMS) which supports active involvement of patients and patient representatives. The result will be better and faster development of new drugs that meet patient needs and improve patient experience.
This goal is in line with Servier’s “Patient-In” policy and fits with the vocation and the values driving the Group since its foundation. In joining the PFMD partnership, the Servier Group recognizes the strategic importance of patient engagement and the quality of the work delivered collectively by PFMD and its members. By accessing and contributing to the knowledge and experience of leading healthcare stakeholders in a way that is agile and globally actionable, Servier confirms its commitment to co-creating the future of patient engagement.
“By becoming an active member of the largest patient-centred international community, we will be able to create and adopt new tools, skills and practices to deploy our “Patient-In” strategy much faster and more effectively. This collaboration serves only one purpose: to develop ever more effective treatments to better meet patients’ needs. This is Servier’s vocation”, said Olivier Laureau, President of Servier.
Servier joins a growing list of first movers and contributors who are shaping and building the conditions for a new age of patient engagement. These include pharmaceutical companies, patient advocacy organizations, healthcare providers and research institutes from the public and private sectors.
Nicholas Brooke, PFMD Chief Executive said: “As major health and technological trends converge, the tipping point is approaching fast – but few are ready for this new era. While it will lead to better care and better treatment, this paradigm shift will open the door to a world of opportunities for people and organizations who have anticipated it. Those who fail to prepare, in fact prepare to fail”.
Servier is an international pharmaceutical company governed by a non-profit foundation, with headquarters in France (Suresnes). With a strong international presence in 149 countries and a turnover of 4.184 billion euros in 2018, Servier employs 21 700 people worldwide. Entirely independent, the Group reinvests 25% of its turnover (princeps drugs) in research and development and uses all its profits for the research and development of new therapeutic solutions. Corporate growth is driven by Servier’s constant search for innovation in five areas of excellence: cardiovascular, immune-inflammatory and neuropsychiatric diseases, cancer and diabetes, as well as by its activities in high-quality generic drugs. Servier also offers eHealth solutions beyond drug development.
More information: www.servier.com
Patient Focused Medicines Development (PFMD) is a not-for-profit organization incubated and powered by The Synergist. PFMD aims to transform the way in which we understand, engage, and partner with patients globally in the design and development of research and medicines WITH patients. PFMD was established in October 2015 as an open, independent global coalition of health stakeholders and currently comprises 28 partners.
More information: www.PFMD.com